Navigation Links
3-V Biosciences to Present Data at the AACR 2017 Annual Meeting in Washington, DC

MENLO PARK, Calif., March 31, 2017 /PRNewswire/ -- 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology and metabolic diseases, announced today that it will present data from its ongoing Phase 1 clinical study of TVB-2640 in solid tumor patients at the AACR annual meeting in Washington, D.C. The abstract "First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640" has been selected for an oral presentation as part of a mini-symposium session titled "Novel Agent and Intervention Clinical Trials" on April 4, 2017 at 4:05PM local time. The Principal Investigator presenting details about the trial is Dr. Gerald Falchook from the Sarah Cannon Research Institute at HealthONE, Denver, CO.

"As the first-in-human study now nears completion, we are very encouraged by the safety of, and preliminary activity seen with TVB-2640 in this group of highly pre-treated patients.  We are especially encouraged by the activity seen in KRAS mutant NSCLC, breast and ovarian cancers which will be described in more detail during the session at AACR", said Dr. Gerald Falchook. "We look forward to further development in Phase II studies, particularly given the poor prognosis and lack of effective therapies that target KRAS mutant NSCLC."

Presentation date: 4/4/2017

Presentation time: 4:05pm local time

Speaker: Dr. Gerald Falchook

About 3-V Biosciences

3-V Biosciences, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics in oncology and liver diseases based on expertise in lipid biology. The company's lead product candidate is a first-in-class inhibitor of fatty acid synthase (FASN) currently being evaluated in a Phase 1 clinical trial. Lipids are integral to cellular metabolism, cellular signaling and cellular structure and the emerging understanding of lipid biology opens up promising new areas for drug development. The company is located in Menlo Park, California.

Contact Information
Dennis Hom
Corporate Development & Finance
(650) 561-8600

To view the original version on PR Newswire, visit:

SOURCE 3-V Biosciences, Inc.
Copyright©2017 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
2. Neurocrine Biosciences to Present At The Deutsche Bank 38th Annual dbAccess Health Care Conference
3. Pressure BioSciences, Inc. to Present at the Marcum MicroCap Conference
4. Neurocrine Biosciences to Present at the Jefferies 2013 Global Healthcare Conference
5. Lilly Statement on Indiana Biosciences Research Institute
6. Pressure BioSciences Announces Core Technology Breakthrough
7. Alzheimers Drug Discovery Foundation Supports Madera Biosciences to Advance Small Molecule Drugs that Upregulate apoE
8. New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research
9. 3-V Biosciences Completes $20 Million Series C Financing
10. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
11. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
Post Your Comments:
(Date:8/16/2019)... ... August 16, 2019 , ... SignatureCare Emergency Center has ... Houston, TX including Montrose, Heights, Memorial City, and Bellaire, TX. , The one-day ... Heights, is aimed at helping Houston families get their children caught up on ...
(Date:8/16/2019)... (PRWEB) , ... August 16, 2019 , ... ... Road in Gainesville GA, 30501, is a comprehensive family dental practice that serves ... within general dentistry, cosmetic dentistry , endodontics and restorative dental care. The ...
(Date:8/16/2019)... ... August 16, 2019 , ... OCT Clinical ... it has successfully completed enrollment of 690 patients for a phase III efficacy ... multicenter, randomized, double-blind, placebo-controlled, home use, parallel group clinical trial of MED2002, which ...
Breaking Medicine Technology:
(Date:8/16/2019)... ... August 16, 2019 , ... ... has joined the esteemed Haute Beauty Network. , The Haute Beauty Network, well ... present Dr. Arnaoutakis as a hair restoration expert and our newest addition to ...
(Date:8/15/2019)... ... ... students either starting college for the first time, and returning to school, the number of ... “there are about 20 million new cases of STDs each year in the United States. ... Young people are at greater risk of getting an STD.” To that end, myLAB ...
(Date:8/14/2019)... ... August 14, 2019 , ... Teguar Corporation has claimed the ... This list has long-been established as a mark of success for some of Americas ... Oracle. Teguar made the list in 2015, 2016 and 2017. This year, Teguar secured ...
(Date:8/14/2019)... Calif. (PRWEB) , ... August 15, 2019 , ... ... its first international clinic in Tijuana Mexico. R3 Stem Cell International is offering ... appropriately licensed in Mexico. , A full procedure costs only $2950, which includes ...
(Date:8/14/2019)... ... August 13, 2019 , ... In a recent Trivedi Effect ... doubt in your belief systems. , “Doubt can obliterate your old beliefs,” said Master ... to examining them to expand your understanding and your awareness. Trust that the Divine ...
Breaking Medicine News(10 mins):